[BACK]
Indication
ActHIB vaccine is indicated for the active immunization of infants and children 2 through 18 months of age for prevention of invasive Haemophilus influenzae type b disease.
Safety Information
The most common local and systemic adverse reactions to ActHIB vaccine include injection site erythema, swelling, and tenderness; fever irritability, drowsiness, and anorexia. Other adverse reactions may occur. ActHIB vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Vaccination with ActHIB vaccine may not protect all individuals.
Before administering ActHIB vaccine, please see accompanying full Prescribing Information.
View full Prescribing Information for ActHIB vaccine. [MORE]
Reference: 1. Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book. 9th ed. Washington, DC: Public Health Foundation; 2006:111-123. 2. ActHIB vaccine Prescribing Information, September 2000. 3. CDC. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)—United States, 1991–2001. MMWR. 2003;52:1-24.
[BACK] |
